Neurocrine Biosciences Inc. (NBIX)

114.71
1.10 0.98
NASDAQ : Health Technology
Prev Close 113.60
Open 113.86
Day Low/High 112.25 / 115.20
52 Wk Low/High 50.88 / 120.90
Volume 333.04K
Avg Volume 644.70K
Exchange NASDAQ
Shares Outstanding 90.47M
Market Cap 10.31B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences Reports Second Quarter 2018 Financial Results

Neurocrine Biosciences Reports Second Quarter 2018 Financial Results

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2018 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Tuesday, July 31

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Chief Executive Officer Of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego

Chief Executive Officer Of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego

SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.

Spring Cleaning: Let's Tidy Up Some Trades

Spring Cleaning: Let's Tidy Up Some Trades

Not every trade can be a winner, so let's lighten the load here.

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2018 Healthcare Conference

Live Audio Webcast Will be on May 15, 2018

Neurocrine Biosciences Presents New Quality Of Life Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia In Patients Treated With Antipsychotics

- Nearly 28 Percent of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia

Neurocrine Biosciences To Present New Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia Patients, At The 2018 American Psychiatric Association Annual Meeting

New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Neurocrine Biosciences Presents New Data Analyses At AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions

Additional Long-Term Data Show INGREZZA Sustained Improvement of Tardive Dyskinesia Symptoms Through 48 Weeks of Treatment and was Well-Tolerated

Neurocrine Biosciences Announces Conference Call And Webcast Of First Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Monday, April 30

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

TheStreet Quant Rating: C (Hold)